Opinion|Videos|September 25, 2024 (Updated: September 25, 2024)
Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics
Experts in the management of mood disorders comment on the evolving management of major depressive disorder, emphasizing findings from the STAR*D trial, updated treatment guidelines, and the role of precision medicine and the shift toward personalized, rapid-acting treatments to improve patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Check out our pipeline updates from September!
Don't miss out on these CME articles! Test your knowledge here.
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Advertisement
Advertisement